Literature DB >> 15389779

Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.

Mac A Johnson1, Philip Iversen, Phillip Schwier, Angela L Corn, George Sandusky, Jeremy Graff, Blake Lee Neubauer.   

Abstract

BACKGROUND: Androgen-deprivation remains the standard of care for metastatic prostate cancer, yet its total impact on the course of disease is incompletely established.
METHODS: We have examined the long-term effects of castration upon the progression of established cancer in the TRAMP transgenic mouse model of prostate cancer. Mice castrated at 15-weeks of age, as well as intact littermates, were followed until spontaneous death from cancer.
RESULTS: Statistical analyses of age-at-death versus primary tumor mass revealed that mice segregate into two categories of response to androgen-deprivation. In Category One, the act of castration paradoxically triggers the growth of microscopic androgen-independent lesions, as evidenced by a statistical synchronization of primary tumor growth. Delaying castration until 20-weeks of age delays the synchronized growth of these tumors, as well as the deaths of the host mice. In Category Two, castration eliminates or substantially delays primary tumor growth, but fails to eliminate metastases. so that castration is found to impart no long-term survival advantage.
CONCLUSIONS: We propose a two-step model for the alteration of androgen signaling in prostate cancer capable of explaining the above paradoxical results, which is based upon the dualistic role of androgens as both survival and differentiation factors. This model makes specific predictions for clinical intervention that are discussed in light of published studies. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15389779     DOI: 10.1002/pros.20148

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.

Authors:  Jake Higgins; Michele Brogley; Nallasivam Palanisamy; Rohit Mehra; Michael M Ittmann; Jun Z Li; Scott A Tomlins; Diane M Robins
Journal:  Horm Cancer       Date:  2015-01-29       Impact factor: 3.869

Review 2.  Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-03-17

3.  Early and delayed castrations confer a similar survival advantage in TRAMP mice.

Authors:  Zai-Xian Zhang; Qing-Quan Xu; Xiao-Bo Huang; Ji-Chuan Zhu; Xiao-Feng Wang
Journal:  Asian J Androl       Date:  2009-04-27       Impact factor: 3.285

4.  Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.

Authors:  Wendy J Huss; Danny R Gray; Keyvan Tavakoli; Meghan E Marmillion; Lori E Durham; Mac A Johnson; Norman M Greenberg; Gary J Smith
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

5.  Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.

Authors:  Jill K Slack-Davis; E Daniel Hershey; Dan Theodorescu; Henry F Frierson; J Thomas Parsons
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

6.  Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer.

Authors:  Orla A O'Mahony; Mara P Steinkamp; Megan A Albertelli; Michele Brogley; Haniya Rehman; Diane M Robins
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

7.  Androgen receptor variants and prostate cancer in humanized AR mice.

Authors:  Diane M Robins; Megan A Albertelli; Orla A O'Mahony
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-07       Impact factor: 4.292

8.  MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice.

Authors:  Maximilian Marhold; Simon Udovica; Thais Topakian; Peter Horak; Reinhard Horvat; Erwin Tomasich; Gerwin Heller; Michael Krainer
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

9.  Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.

Authors:  Giorgio Mauri; Elena Jachetti; Barbara Comuzzi; Matteo Dugo; Ivano Arioli; Silvia Miotti; Sabina Sangaletti; Emma Di Carlo; Claudio Tripodo; Mario P Colombo
Journal:  Oncotarget       Date:  2016-01-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.